Loading...
XNAS
NAOV
Market cap2mUSD
Jun 06, Last price  
0.90USD
1D
-6.26%
1Q
151.47%
Jan 2017
-84.90%
IPO
-74.29%
Name

Nanovibronix Inc

Chart & Performance

D1W1MN
P/E
—
P/S
0.91
EPS
—
Div Yield, %
—
Shrs. gr., 5y
50.72%
Rev. gr., 5y
37.00%
Revenues
3m
+12.05%
94,000166,000211,000203,000147,000229,000239,000318,000530,000623,0001,695,000752,0002,283,0002,558,000
Net income
-4m
L-0.16%
-723,000-1,275,000-1,989,000-2,647,000-2,884,000-2,831,000-4,965,000-4,154,000-5,794,000-4,326,000-14,282,000-5,448,000-3,711,000-3,705,000
CFO
-3m
L-30.15%
-547,000-787,000-602,000-900,000-1,480,000-1,533,000-2,182,000-3,550,000-3,874,000-3,391,000-4,367,000-7,035,000-3,602,000-2,516,000
Earnings
Aug 12, 2025

Profile

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
URL
https://nanovibronix.com/
IPO date
Apr 24, 2015
Employees
9
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,558
12.05%
2,283
203.59%
752
-55.63%
Cost of revenue
6,140
5,719
5,764
Unusual Expense (Income)
NOPBT
(3,582)
(3,436)
(5,012)
NOPBT Margin
Operating Taxes
(19)
29
35
Tax Rate
NOPAT
(3,563)
(3,465)
(5,047)
Net income
(3,705)
-0.16%
(3,711)
-31.88%
(5,448)
-61.85%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,215
2,090
BB yield
-209.43%
-584.20%
Debt
Debt current
52
10
81
Long-term debt
180
5
162
Deferred revenue
15
107
Other long-term liabilities
216
217
142
Net debt
(520)
(3,268)
(2,473)
Cash flow
Cash from operating activities
(2,516)
(3,602)
(7,035)
CAPEX
(3)
(1,000)
(3)
Cash from investing activities
(3)
(1,000)
(3)
Cash from financing activities
1,000
4,222
2,092
FCF
(2,916)
(4,091)
(5,139)
Balance
Cash
752
3,283
2,713
Long term investments
3
Excess cash
624
3,169
2,678
Stockholders' equity
(69,878)
(66,161)
(62,401)
Invested Capital
70,837
70,391
66,045
ROIC
ROCE
EV
Common stock shares outstanding
2,698
1,750
1,420
Price
0.59
-48.70%
1.15
356.35%
0.25
-75.77%
Market cap
1,592
-20.89%
2,013
462.57%
358
-72.66%
EV
1,072
(1,255)
(2,115)
EBITDA
(3,581)
(3,435)
(5,011)
EV/EBITDA
0.37
0.42
Interest
135
246
347
Interest/NOPBT